Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2017

  • ID: 4418962
  • Report
  • 67 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allinky Biopharma
  • Array BioPharma Inc
  • AstraZeneca Plc
  • Chiesi Farmaceutici SpA
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • MORE
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Pipeline Review, H2 2017

Summary

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2017, outlays comprehensive information on the Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family. p38-alpha MAPK play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. p38-alpha MAPK is expressed in many cell types. p38-alpha MAPK is implicated in cell apoptosis, proliferation, differentiation, migration, mRNA stability, and inflammatory response in different cell types through variety of different target molecules. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 5, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Oncology, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Ophthalmology, Respiratory and Undisclosed which include indications Alzheimer's Disease, Pancreatic Cancer, Acute Ischemic Stroke, Age Related Macular Degeneration, Breast Cancer, Chronic Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Dilated Cardiomyopathy, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Focal Segmental Glomerulosclerosis (FSGS), Gastric Cancer, Glioblastoma Multiforme (GBM), Ischemic Stroke, Liver Cancer, Lung Cancer, Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Small Cell Lung Cancer, Peritoneal Cancer, Rheumatoid Arthritis, Ulcerative Colitis and Unspecified.

Furthermore, this report also reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)
  • The report reviews Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allinky Biopharma
  • Array BioPharma Inc
  • AstraZeneca Plc
  • Chiesi Farmaceutici SpA
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • MORE
Introduction

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Overview

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Companies Involved in Therapeutics Development

Allinky Biopharma

Array BioPharma Inc

AstraZeneca Plc

Chiesi Farmaceutici SpA

Eli Lilly and Co

GlaxoSmithKline Plc

Synovo GmbH

TopiVert Ltd

Zocere Inc

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Drug Profiles

AIK-3a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHF-6297 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

losmapimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neflamapimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pamapimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit MAPK14 and MAPK11 for Rheumatoid Arthritis, Multiple Sclerosis and Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ralimetinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit MAPK14 for Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Mitogen Activated Protein Kinase 14 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit p38alpha MAP Kinase for Chronic Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYD-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Dormant Products

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Discontinued Products

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Product Development Milestones

Featured News & Press Releases

Jul 18, 2017: EIP Pharma announces presentation of new positive clinical data with neflamapimod at Alzheimer's Association International Conference

Dec 08, 2016: EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer’s Disease

Nov 16, 2016: EIP Pharma announces upcoming oral presentations of Phase 2a clinical trial results with neflamapimod (VX-745) at Clinical Trials in Alzheimer's Disease (CTAD) conference Dec 8-10,

Sep 28, 2016: EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimers disease and ischemic stroke recovery

Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress

Aug 20, 2016: Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress

Dec 16, 2015: EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor

Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)

Jul 15, 2015: Zocere's Brain Saving” Drug Issued U.S. Patent

Jun 03, 2015: EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease

Jan 07, 2015: Zocere to Present Brain-Protecting Drug at Biotech Showcase

Oct 14, 2014: Zocere Showcases “Brain Saving” Drug at Life Sciences Summit in New York City

Oct 01, 2014: Zocere’s Stroke Drug to Be Featured at BIO Investor Forum

Sep 23, 2014: Public summary of opinion on orphan designation

Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indications, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by Allinky Biopharma, H2

Pipeline by Array BioPharma Inc, H2

Pipeline by AstraZeneca Plc, H2

Pipeline by Chiesi Farmaceutici SpA, H2

Pipeline by Eli Lilly and Co, H2

Pipeline by GlaxoSmithKline Plc, H2

Pipeline by Synovo GmbH, H2

Pipeline by TopiVert Ltd, H2

Pipeline by Zocere Inc, H2

Dormant Products, H2

Discontinued Products, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allinky Biopharma
  • Array BioPharma Inc
  • AstraZeneca Plc
  • Chiesi Farmaceutici SpA
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Synovo GmbH
  • TopiVert Ltd
  • Zocere Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll